Taiwan Exosome BioTherapeutics Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
Orthopedic/Dental Bone Graft and Filling Materials, Periodontal Regeneration Membrane
The content above was translated by Ai
Founded Year
2022
Unified Business No.
89155391
Status
Active
Number of Employees
2
Total Paid-in
Capital
3,000,000 (NT$)
Location of Company
Taiwan
, New Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taiwan Exosome BioTherapeutics Co., Ltd. is dedicated to developing and applying cells, their derivatives, and related biomedical materials, such as orthopedic/dental filling materials and periodontal regenerative membranes, to oral tissue reconstruction. Using the twenty years of cell testing experience of its founder, Dr. Wen-Chun Kuo, as a bridge, the company combines academic research with industrial development to develop new medical biomedical composite materials.
In July 2022, it was officially licensed to Taiwan Exosome BioTherapeutics Co., Ltd. for product development and the optimization of biomedical material manufacturing processes, moving forward toward applying for Class II medical devices.
In July 2022, it was officially licensed to Taiwan Exosome BioTherapeutics Co., Ltd. for product development and the optimization of biomedical material manufacturing processes, moving forward toward applying for Class II medical devices.
The content above was translated by Ai
